Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives.

Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate has been observed owing to a greater awareness of its broad clinical presentation. Cardiac amyloidosis is frequently associated to specific clinical and instrumental features, so called "red flags", and it appears to occur more commonly in particular clinical settings such as multidistrict orthopedic conditions, aortic valve stenosis, heart failure with preserved or mildly reduced ejection fraction, arrhythmias, plasma cell disorders. Multimodality approach and new developed techniques such PET fluorine tracers or artificial intelligence may contribute to strike up extensive screening programs for an early recognition of the disease.

© 2023 Caponetti, Accietto, Saturi, Ponziani, Sguazzotti, Massa, Giovannetti, Ditaranto, Parisi, Leone, Guaraldi, Cortelli, Gagliardi, Longhi, Galiè and Biagini.

Overview publication

TitleScreening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives.
Date2023-01-01
Issue nameFrontiers in cardiovascular medicine
Issue numberv10:1146725
DOI10.3389/fcvm.2023.1146725
PubMed36970351
AuthorsCaponetti AG, Accietto A, Saturi G, Ponziani A, Sguazzotti M, Massa P, Giovannetti A, Ditaranto R, Parisi V, Leone O, Guaraldi P, Cortelli P, Gagliardi C, Longhi S, Galiè N & Biagini E
KeywordsAL, ATTR, aortic stenosis, cardiac amyloidosis, heart failure, nuclear medicine, screening
Read Read publication